TY - JOUR
T1 - Palladium(II) and platinum(II) organometallic complexes with the model nucleobase anions of thymine, uracil, and cytosine: Antitumor activity and interactions with DNA of the platinum compounds
AU - Ruiz, José
AU - Lorenzo, Julia
AU - Sanglas, Laura
AU - Cutillas, Natalia
AU - Vicente, Consuelo
AU - Villa, María Dolores
AU - Avilés, Francesc X.
AU - López, Gregorio
AU - Moreno, Virtudes
AU - Pérez, José
AU - Bautista, Delia
PY - 2006/8/7
Y1 - 2006/8/7
N2 - Pd(II) and Pt(II) complexes with the anions of the model nucleobases 1-methylthymine (1-MethyH), 1-methyluracil (1-MeuraH), and 1-methylcytosine (1-MecytH) of the types [Pd(dmba)(μ-L)]2 [dmba = N,C-chelating 2-((dimethyl-amino)methyl)phenyl; L = 1-Methy, 1-Meura or 1-Mecyt] and [M(dmba)(L)(L′)] [L = 1-Methy or 1-Meura; L′ = PPh3 (M = Pd or Pt), DMSO (M = Pt)] have been obtained. Palladium complexes of the types [Pd(C6F5)(N-N)(L)] [L = 1-Methy or 1-Meura; N-N = N,N,N′,N′-tetramethylethylenediamine (tmeda), 2,2′-bipyridine (bpy), or 4,4′-dimethyl-2,2′-bipyridine (Me2bpy)] and [NBu4][Pd(C6F5)(1-Methy)2(H 2O)] have also been prepared. The crystal structures of [Pd(dmba)(μ-1-Methy)]2, [Pd(dmba)(μ-1-Mecyt)] 2·2CHCl3, [Pd(dmba)(1-Methy)(PPh 3)]·3CHCl3, [Pt(dmba)(1-Methy)(PPh3)], [Pd(tmeda)(C6F5)(1-Methy)], and [NBu4] [Pd(C6F5)(1-Methy)2(H2O)] ·H2O have been established by X-ray diffraction. The DNA adduct formation of the new platinum complexes synthesized was followed by circular dichroism and electrophoretic mobility. Atomic force microscopy images of the modifications caused by the platinum complexes on plasmid DNA pBR322 were also obtained. Values of IC50 were also calculated for the new platinum complexes against the tumor cell line HL-60. All the new platinum complexes were more active than cisplatin (up to 20-fold in some cases). © 2006 American Chemical Society.
AB - Pd(II) and Pt(II) complexes with the anions of the model nucleobases 1-methylthymine (1-MethyH), 1-methyluracil (1-MeuraH), and 1-methylcytosine (1-MecytH) of the types [Pd(dmba)(μ-L)]2 [dmba = N,C-chelating 2-((dimethyl-amino)methyl)phenyl; L = 1-Methy, 1-Meura or 1-Mecyt] and [M(dmba)(L)(L′)] [L = 1-Methy or 1-Meura; L′ = PPh3 (M = Pd or Pt), DMSO (M = Pt)] have been obtained. Palladium complexes of the types [Pd(C6F5)(N-N)(L)] [L = 1-Methy or 1-Meura; N-N = N,N,N′,N′-tetramethylethylenediamine (tmeda), 2,2′-bipyridine (bpy), or 4,4′-dimethyl-2,2′-bipyridine (Me2bpy)] and [NBu4][Pd(C6F5)(1-Methy)2(H 2O)] have also been prepared. The crystal structures of [Pd(dmba)(μ-1-Methy)]2, [Pd(dmba)(μ-1-Mecyt)] 2·2CHCl3, [Pd(dmba)(1-Methy)(PPh 3)]·3CHCl3, [Pt(dmba)(1-Methy)(PPh3)], [Pd(tmeda)(C6F5)(1-Methy)], and [NBu4] [Pd(C6F5)(1-Methy)2(H2O)] ·H2O have been established by X-ray diffraction. The DNA adduct formation of the new platinum complexes synthesized was followed by circular dichroism and electrophoretic mobility. Atomic force microscopy images of the modifications caused by the platinum complexes on plasmid DNA pBR322 were also obtained. Values of IC50 were also calculated for the new platinum complexes against the tumor cell line HL-60. All the new platinum complexes were more active than cisplatin (up to 20-fold in some cases). © 2006 American Chemical Society.
U2 - https://doi.org/10.1021/ic060374e
DO - https://doi.org/10.1021/ic060374e
M3 - Article
VL - 45
SP - 6347
EP - 6360
ER -